1. Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
May 29 - June 2, 2015
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
CRC, colorectal cancer.
This program is supported by educational grants from AstraZeneca, Bayer, Celgene Corporation, Genentech, Incyte, and Novartis.

2. Aspirin as Secondary Prevention in CRC: Background
Regular aspirin use associated with reduced CRC incidence and mortality[1,2]
Utility as primary prevention in general population debatable given risk of serious hemorrhagic adverse effects
Utility as secondary prevention may be more justified from risk–benefit prospective and considering that aspirin reverses tumor immune evasion in established CRC
Current observational study represents largest cohort ever examined evaluating effects of aspirin as secondary prevention[3]
CRC, colorectal cancer.
1. Lii P, et al. Gut. 2014;[Epub ahead of print]. 2. Flossmann E, et al. Lancet. 2007;369: Bains S, et al. ASCO Abstract 3504.

3. Aspirin as Secondary Prevention in CRC: Study Design
Observational population-based cohort study in Norway
Cancer Registry of Norway and Norwegian Prescription Database used to retrospectively link pts diagnosed with CRC from and their use of aspirin
Aspirin use defined as aspirin prescription for > 6 mos following CRC diagnosis
Registries cover > 99% of Norwegian population and provide high-quality, validated data
Primary endpoints: OS, cancer-specific survival
CRC, colorectal cancer; OS, overall survival.
Bains S, et al. ASCO Abstract 3504.

4. Aspirin as Secondary Prevention in CRC: Baseline Characteristics
Aspirin Use
P Value No
(n = 19,535)
Yes
(n = 6109)
Mean age, yrs
70.0
74.0 NR
Male, %
48.8
56.4
< .001
Tumor differentiation, %
Well
Moderate
Poor
Undifferentiated
6.0
60.9
18.2
0.2
7.2
65.9
14.3
Site of disease, %
Right
Transverse
Left
Rectum
30.9
6.9
26.3
34.2
32.7
6.6
26.4
32.9
.042
CRC, colorectal cancer; NR, not reported.
Bains S, et al. ASCO Abstract 3504.

5. Aspirin as Secondary Prevention in CRC: Baseline Characteristics continued
Aspirin Use
P Value No
(n = 19,535)
Yes
(n = 6109)
AJCC disease stage I II
III IV
20.3
27.1
26.6
23.6
26.0
34.5
26.2
9.4
< .001
Survival status
Alive
Dead due to CRC
Dead due to other reasons
Dead due to reasons unknown
61.1
32.5
5.2
1.1
65.8
19.2
10.9
4.1
Underwent primary surgery
88.1
95.8
.08
AJCC, American Joint Committee on Cancer; CRC, colorectal cancer.
Bains S, et al. ASCO Abstract 3504.

6. Aspirin as Secondary Prevention in CRC: OS and CSS
Survival Outcome
Univariate Analysis
Multivariate Analysis
HR (95% CI)
P Value OS
1.03 ( )
.25
0.86 ( )
< .001
CSS
0.84 ( )
0.75 ( )
CRC, colorectal cancer; CSS, cancer-specific survival; OS, overall survival.

7. Aspirin as Secondary Prevention in CRC: Conclusions
In a cohort of more than 25,000 Norwegian individuals, aspirin use after CRC diagnosis independently associated with improved clinical outcomes
Risk of CRC-specific mortality reduced by 25%
Risk of all-cause mortality reduced by 14%
CRC, colorectal cancer.
Bains S, et al. ASCO Abstract 3504.

8. Go Online for More CCO Coverage of ASCO 2015!
Short slidesets of all the key data
Additional CME-certified analyses with expert faculty commentary on all the key studies in:
Gastrointestinal cancers
Lung cancer
Hematological malignancies
Immunotherapy
Genitourinary cancer
clinicaloptions.com/oncology